Everything below concerns lipodystrophy. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-17. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
On November 28, 2025, The Washington Post published an article alleging Hegseth had given a spoken order to kill the survivors of a September 2, 2025, strike led by SEAL Team 6 on a boat suspected of carrying drugs in the Caribbean Sea. The operation was overseen by Admiral Frank M. "Mitch" Bradley, from Fort Bragg in North Carolina. Bradley described the survivors as legitimate targets, as they could theoretically have contacted other traffickers to rescue them and their cargo, and subsequently ordered the second strike to complete Hegseth's order that everyone must be killed. Hegseth's explanation for the strike has shifted over time. The Office of Legal Counsel eventually argued that the strike was legal because its goal was to destroy the boat, not to kill the crew, reflecting a secret legal memo endorsing such strikes; the memo has been "fiercely criticized" by legal experts. The strike was the first in a series of strikes against suspected drug traffickers. Hegseth's alleged orders were characterized by several legal experts as murder and a war crime. The alleged orders were condemned by members of congress, including Representative Seth Moulton, who said "Mark my words: It may take some time, but Americans will be prosecuted for this, either as a war crime or outright murder." Both Senators Tim Kaine and Mark Kelly described the alleged orders as a war crime.
In the 21st century, the university has seen the construction of a new student union, two dedicated parking garages, the Earl S. Richardson Library, the Dixon Research Center, the Communications Building, and the Center for the Built Environment and Infrastructure Studies. The Carl J. Murphy Fine Arts Center is also the home of the James E. Lewis Museum of Art. In September 2012, Morgan State opened the Center for the Built Environment and Infrastructure Studies (CBEIS) which houses the School of Architecture and Planning, School of Transportation Studies, and the School of Engineering. In 2020, MacKenzie Scott donated $40 million to Morgan State. The following year, Calvin E. Tyler Jr. donated $20 million to endow scholarships. In 2025, MacKenzie Scott donated an additional $63 million to Morgan State, the largest donation in the history of the institution. The National Trust for Historic Preservation has designated Morgan State University as a National Treasure, the only such honor for a college or university campus in the United States. The neighboring Morgan Park Historic District was listed on the National Register of Historic Places in 2020.
== Development == C-4 is a member of the Composition C family of chemical explosives. Variants have different proportions and plasticisers and include compositions C-2, C-3, and C-4. The original RDX-based material was developed by the British during World War II and redeveloped as Composition C when introduced to the U.S. military. It was replaced by Composition C-2 around 1943 and later redeveloped around 1944 as Composition C-3. The toxicity of C-3 was reduced, the concentration of RDX was increased, giving it improved safety during usage and storage. Research on a replacement for C-3 was begun prior to 1950, but the new material, C-4, did not begin pilot production until 1956. C-4 was submitted for patent as "Solid Propellant and a Process for its Preparation" March 31, 1958, by the Phillips Petroleum Company.
Sources: en.wikipedia.org
where M is the analyte molecule being ionized, e− is the electron and M+• is the resulting molecular ion. In an EI ion source, electrons are produced through thermionic emission by heating a wire filament that has electric current running through it. The kinetic energy of the bombarding electrons should have higher energy than the ionization energy of the sample molecule. The electrons are accelerated to 70 eV in the region between the filament and the entrance to the ion source block. The sample under investigation which contains the neutral molecules is introduced to the ion source in a perpendicular orientation to the electron beam. Close passage of highly energetic electrons in low pressure (ca. 10−5 to 10−6 torr) causes large fluctuations in the electric field around the neutral molecules and induces ionization and fragmentation. The fragmentation in electron ionization can be described using Born Oppenheimer potential curves as in the diagram. The red arrow shows the electron impact energy which is enough to remove an electron from the analyte and form a molecular ion from non- dissociative results. Due to the higher energy supplied by 70 eV electrons other than the molecular ion, several other bond dissociation reactions can be seen as dissociative results, shown by the blue arrow in the diagram. These ions are known as second-generation product ions. The radical cation products are then directed towards the mass analyzer by a repeller electrode.
== Function == Asparagine synthetase is required for normal development of the brain. Asparagine is also involved in protein synthesis during replication of poxviruses. The addition of N-acetylglucosamine to asparagine is performed by oligosaccharyltransferase enzymes in the endoplasmic reticulum. This glycosylation is involved in protein structure and function.
Initially, PKCε was thought to protect mitochondria from MPT through its association with VDAC1, ANT, and hexokinase II; however, genetic studies have since ruled this out and subsequent studies have identified the F0/F1 ATP synthase as a core inner mitochondrial membrane component and Bax and Bak as potential outer membrane components These findings have opened up new avenues of investigation for the role of PKCε at mitochondria. Several likely targets of PKCε action affecting MPT have been discovered. PKCε interacts with ERK, JNKs and p38, and PKCε directly or indirectly phosphorylates ERK and subsequently Bad. PKCε also interacts with Bax in cancer cells, and PKCε modulates its dimerization and function. Activation of PKCε with the specific activator, εRACK, prior to ischemic injury has shown to be associated with phosphorylation of the F0/F1 ATP synthase. Moreover, the modulatory component, ANT is regulated by PKCε. These data suggest that PKCε may act at multiple modulatory targets of MPT function; further studies are required to unveil the specific mechanism.
Sources: en.wikipedia.org
==== Knight Commander of the Order of St Michael and St George (KCMG) ==== Thomas Drew, , Director General, Defence and Intelligence, Foreign, Commonwealth and Development Office. For services to British Foreign Policy and National Security. Richard Grenville Russell Evans, Chairman, Hemingways Hospitality Ltd. For services to Business, to Sport and to Charity. Crawford Falconer, Chief Trade Negotiation Adviser and Second Permanent Secretary, Department for Business and Trade. For services to International Trade.
== Laboratory directors == Clinical laboratories in the US that perform high complexity testing require a high complexity laboratory director (HCLD) who has earned a doctoral degree in chemical, physical, biological, or clinical laboratory science from an accredited institution and is certified by, and remains certified by, a board approved by HHS. The current approved boards are the following:
== References == Carpenter, Kenneth (1999). Eggs, Nests, and Baby Dinosaurs: A Look at Dinosaur Reproduction (Life of the Past), Indiana University Press; ISBN 0-253-33497-7. Deeming, D. C. and M. W. J. Ferguson (eds.) 1991. Egg incubation: its effect on embryonic development in birds and reptiles. Cambridge University Press, UK. 448pp. Glut, Donald F. (2003), "Appendix: Dinosaur Tracks and Eggs", Dinosaurs: The Encyclopedia. 3rd Supplement, Jefferson, North Carolina: McFarland & Company, Inc., pp. 613–652, ISBN 978-0-7864-1166-5 Horner, John R.; Weishampel, David B. (1996). "A comparative embryological study of two ornithischian dinosaurs - a correction". Nature. 383 (6595): 256–257. Bibcode:1996Natur.383..103H. doi:10.1038/383103b0. Mateus, I; Mateus, H; Antunes, MT; Mateus, O; Taquet, P; Ribeiro, V; Manuppella, G (1998). "Upper Jurassic theropod dinosaur embryos from Lourinhã (Portugal)". Memórias da Academia das Ciências de Lisboa. 37: 101–110. Moskvitch, Katia. "Eggs with the Oldest Known Embryos of a Dinosaur Found". BBC News. November 12, 2010. de Ricqlès, A.; Mateus, O.; Antunes, M. T.; Taquet, P. (2001). "Histomorphogenesis of embryos of Upper Jurassic theropods from Lourinhã (Portugal)". Comptes Rendus de l'Académie des Sciences, Série IIA. 332 (10): 647–656. Bibcode:2001CRASE.332..647D. doi:10.1016/s1251-8050(01)01580-4. Reisz, Robert R.; Scott, Diane; Sues, Hans-Dieter; Evans, David C.; Raath, Michael A. (2005). "Embryos of an Early Jurassic prosauropod dinosaur and their evolutionary significance" (PDF). Science. 309 (5735): 761–764.
== Function == Nicotinamide phosphoribosyltransferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.